The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

Since April 2022, enfortumab vedotin has been approved for the treatment of pretreated adults with locally advanced or metastatic ... survival advantage for bladder cancer patients for whom ...

Bladder cancer stands as one of ... To find out how Enfortumab vedotin and pembrolizumab together affected patients with advanced urothelial cancer in patients who have not received treatment ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

Since April 2022, enfortumab vedotin has been approved for the treatment of pretreated adults with locally advanced or metastatic ... survival advantage for bladder cancer patients for whom ...

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in ...

The FDA has started a priority review of Seattle Genetics and Astellas’ antibody-drug conjugate enfortumab vedotin ... advanced urothelial carcinoma (UC) – the most common form of bladder ...

Since April 2022, enfortumab vedotin has been approved for the treatment of pretreated adults with locally advanced or metastatic ... survival advantage for bladder cancer patients for whom ...

Results of a meta-analysis suggest that enfortumab vedotin plus pembrolizumab is more effective than chemotherapy as first-line treatment for patients with metastatic urothelial cancer ...